Cancer Research and Treatment

Original Articles

Gynecologic cancer

Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period: Tae Hoon Lee, Kyung Su Kim, Hak Jae Kim, Chang Heon Choi, Seonghee Kang, Keun-Yong Eom, Chan Woo Wee, Yong Sang Song, Noh Hyun Park, Jae-Weon Kim, Hyun Hoon Chung, Hee Seung Kim, Maria Lee, Hyun-Cheol Kang; Cancer Res Treat. 2023;55(1):258-269. Published online August 10, 2022; DOI: https://doi.org/10.4143/crt.2022.418

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.
Materials and Methods
Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.
Results
The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.
Conclusion
IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.

Citations

Citations to this article as recorded by

Cisplatin

Reactions Weekly.2023; 1947(1): 125. CrossRef
A Mixed Methods Study to Implement the Synergy Tool and Evaluate Its Impact on Long-Term Care Residents
Farinaz Havaei, Francis Kobekyaa, Andy Ma, Maura MacPhee, Wei Zhang, Megan Kaulius, Bahar Ahmadi, Sheila Boamah, Adam Easterbrook, Amy Salmon
Healthcare.2023; 11(15): 2187. CrossRef

5,328 View
124 Download
1 Web of Science
2 Crossref

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study: Se Ik Kim, Hyunji Lim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Maria Lee; Cancer Res Treat. 2023;55(1):245-257. Published online July 19, 2022; DOI: https://doi.org/10.4143/crt.2022.232

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).
Materials and Methods
We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.
Results
Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).
Conclusion
In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.

4,746 View
162 Download

Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy: Aeran Seol, Ga Won Yim, Joo Yeon Chung, Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong Sang Song; Cancer Res Treat. 2022;54(4):1219-1229. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.1010

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to identify patients who would benefit from third and subsequent lines of chemotherapy in recurrent epithelial ovarian cancer (EOC).
Materials and Methods
Recurrent EOC patients who received third, fourth, or fifth-line palliative chemotherapy were retrospectively analyzed. Patients’ survival outcomes were assessed according to chemotherapy lines. Based on the best objective response, patients were divided into good-response (stable disease or better) and poor response (progressive disease or those who died before response assessment) groups. Survival outcomes were compared between the two groups, and factors associated with chemotherapy responses were investigated.
Results
A total of 189 patients were evaluated. Ninety-four and 95 patients were identified as good and poor response group respectively, during the study period of 2008 to 2021. The poor response group showed significantly worse progression-free survival (median, 2.1 months vs. 9.7 months; p < 0.001) and overall survival (median, 5.0 months vs. 22.9 months; p < 0.001) compared with the good response group. In multivariate analysis adjusting for clinicopathologic factors, short treatment-free interval (TFI) (hazard ratio [HR], 5.557; 95% confidence interval [CI], 2.403 to 12.850), platinum-resistant EOC (HR, 2.367; 95% CI, 1.017 to 5.510), and non-serous/endometrioid histologic type (HR, 5.045; 95% CI, 1.152 to 22.088) were identified as independent risk factors for poor response. There was no difference in serious adverse events between good and poor response groups (p=0.167).
Conclusion
Third and subsequent lines of chemotherapy could be carefully considered for palliative purposes in recurrent EOC patients with serous or endometrioid histology, initial platinum sensitivity, and long TFIs from the previous chemotherapy regimen.

Citations

Citations to this article as recorded by

CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression
Chunyan Huang, Li Qin, Sailan Chen, Qin Huang
Anti-Cancer Drugs.2022;[Epub] CrossRef

5,690 View
146 Download
1 Web of Science
1 Crossref

Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea: Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song; Cancer Res Treat. 2020;52(4):1229-1241. Published online July 27, 2020; DOI: https://doi.org/10.4143/crt.2020.557

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to present a single institutional experience with BRCA1/2 gene tests and the effects of pathogenic mutations in epithelial peritoneal, ovarian, and fallopian tube cancer (POFTC) on survival outcomes.
Materials and Methods
We identified patients with epithelial POFTCs who underwent BRCA1/2 gene testing by either germline or somatic methods between March 2007 and March 2020. Based on the BRCA1/2 test results, patients were divided into BRCA mutation and wild-type groups, followed by comparisons of clinicopathologic characteristics and survival outcomes after primary treatment.
Results
The annual number of POFTC patients who received BRCA1/2 gene tests increased gradually. In total, 511 patients were included and BRCA1/2 mutations were observed in 143 (28.0%). Among 57 patients who received both germline and somatic tests, three (5.3%) showed discordant results from the two tests. Overall, no differences in progression-free survival (PFS; p=0.467) and overall survival (p=0.641) were observed between the BRCA mutation and wild-type groups; however, multivariate analyses identified BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted hazard ratio [aHR], 0.765; 95% confidence interval [CI], 0.593 to 0.987; p=0.040). In 389 patients with International Federation of Gynecology and Obstetrics stage III-IV, different results were shown depending on primary treatment strategy: while BRCA1/2 mutation significantly improved PFS in the subgroup of neoadjuvant chemotherapy (aHR, 0.619; 95% CI, 0.385 to 0.995; p=0.048), it did not affect patient PFS in the subgroup of primary debulking surgery (aHR, 0.759; 95% CI, 0.530 to 1.089; p=0.135).
Conclusion
BRCA1/2 mutations are frequently observed in patients with epithelial POFTCs, and such patients showed better PFS than did those harboring wild-type BRCA1/2.

Citations

Citations to this article as recorded by

Overview of Molecular Diagnostics in Irish Clinical Oncology
Tyler Medina, Seán O. Hynes, Maeve Lowery, Paddy Gillespie, Walter Kolch, Cathal Seoighe
HRB Open Research.2024; 7: 16. CrossRef
Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea
Se Ik Kim, Hyeong In Ha, Kyung Jin Eoh, Jiwon Lim, Young-Joo Won, Myong Cheol Lim
Frontiers in Oncology.2022;[Epub] CrossRef
Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers
Zongbi Yi, Min Chen, Shaoxing Sun, Chunxu Yang, Zijie Mei, Hui Yang, Qingming Xiang, Hui Qiu
Cancer Innovation.2022; 1(3): 220. CrossRef

8,126 View
214 Download
12 Web of Science
3 Crossref

Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer: Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song; Cancer Res Treat. 2019;51(3):1144-1155. Published online November 20, 2018; DOI: https://doi.org/10.4143/crt.2018.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.

Citations

Citations to this article as recorded by

Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer
Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun
BMC Women's Health.2024;[Epub] CrossRef
Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer
Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren
Cancer Medicine.2023; 12(8): 10045. CrossRef
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
Clinical and Molecular Hepatology.2022; 28(1): 105. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Stanislas Quesada, Michel Fabbro, Jérôme Solassol
Cancers.2022; 14(4): 1098. CrossRef
Construction and validation of a transcription factors-based prognostic signature for ovarian cancer
Qingyuan Cheng, Liman Li, Mingxia Yu
Journal of Ovarian Research.2022;[Epub] CrossRef
Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model
Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim
Frontiers in Microbiology.2022;[Epub] CrossRef
Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
Jiayi Li, Dongyan Cao
Frontiers in Oncology.2022;[Epub] CrossRef
Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
Judan Zeng, Wenjiao Cao, Lihua Wang
Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10. CrossRef
Sphingolipids as multifaceted mediators in ovarian cancer
MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson
Cellular Signalling.2021; 81: 109949. CrossRef
Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition
Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang
Scientific Reports.2021;[Epub] CrossRef
Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study
Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park
Journal of Medical Internet Research.2021; 23(4): e25852. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
Cancers.2021; 13(8): 1875. CrossRef
M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu
Frontiers in Oncology.2021;[Epub] CrossRef
Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization
Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu
Current Problems in Cancer.2020; 44(6): 100612. CrossRef
Can we predict who lives long with ovarian cancer?
Michael A. Bookman
Cancer.2019; 125(S24): 4578. CrossRef

10,312 View
266 Download
16 Web of Science
15 Crossref

Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Maria Lee, Yumi Lee, Kidong Kim, Eun Young Park, Myong Cheol Lim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Kim, Jungnam Joo, Sang Yoon Park, Chel Hun Choi, Jae-Hoon Kim; Cancer Res Treat. 2019;51(1):112-118. Published online March 7, 2018; DOI: https://doi.org/10.4143/crt.2017.361

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility.
Materials and Methods
In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated.
Results
Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting.
Conclusion
Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility.

Citations

Citations to this article as recorded by

Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties
Silvia Belloni, Arianna Magon, Chiara Giacon, Francesca Savioni, Gianluca Conte, Rosario Caruso, Cristina Arrigoni
Current Oncology.2024; 31(12): 7828. CrossRef
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review
Charlotte L Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Miek
Future Oncology.2023; 19(9): 663. CrossRef
Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer
Husnu Tore Yavuzsen, Sukriye Cansu Gulteki̇n, Karya Polat, Murat Keser, Zeynep Gulsum Guc, Merve Keskinkilic, Tugba Yavuzsen, Didem Karadibak, Sourav Panja
European Journal of Cancer Care.2023; 2023: 1. CrossRef
Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use
Tiffany Li, Susanna B. Park, Eva Battaglini, Madeleine T. King, Matthew C. Kiernan, David Goldstein, Claudia Rutherford
Quality of Life Research.2022; 31(11): 3091. CrossRef
Influence of chemotherapy on postural control and quality of life in women with gynaecological cancer: a protocol of a prospective observational study
Aline Reinmann, Anne-Violette Bruyneel, Joseph Gligorov, Serge Mesure, Christophe Combescure, Thibaud Koessler, Alexandre Bodmer
BMJ Open.2022; 12(9): e061664. CrossRef

8,325 View
186 Download
5 Web of Science
5 Crossref

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors: Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim; Cancer Res Treat. 2017;49(4):1153-1163. Published online February 27, 2017; DOI: https://doi.org/10.4143/crt.2016.463

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.

Citations

Citations to this article as recorded by

Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists
Jinna Lin, Shuqi Zheng, Qiang Liu
Cancer Treatment Reviews.2025; 133: 102879. CrossRef
Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song
Breast Cancer Research and Treatment.2024; 206(3): 543. CrossRef
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin
Current Oncology.2023; 30(2): 1794. CrossRef
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study
Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk
Annals of Medicine & Surgery.2022;[Epub] CrossRef
Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis
Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias
Medicina.2021; 57(4): 385. CrossRef
Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control
Brändli SP, Palm J, Kowalewski MP, Reichler IM
Theriogenology.2021; 173: 73. CrossRef
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney
Cancer Management and Research.2021; Volume 13: 6537. CrossRef
Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results
Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid
Indian Journal of Surgical Oncology.2019; 10(3): 542. CrossRef
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, Sara Hurvitz
Clinical Cancer Research.2018; 24(21): 5206. CrossRef

12,953 View
367 Download
12 Web of Science
9 Crossref

Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway: Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song; Cancer Res Treat. 2017;49(2):338-349. Published online July 18, 2016; DOI: https://doi.org/10.4143/crt.2016.175

Abstract PDF PubReader ePub

Purpose
Adipose stromal cells (ASCs) play an important regulatory role in cancer progression and metastasis by regulating systemic inflammation and tissue metabolism. This study examined whether visceral and subcutaneous ASCs (V- and S-ASCs) facilitate the growth and migration of ovarian cancer cells.
Materials and Methods
CD45– and CD31– double-negative ASCs were isolated from the subcutaneous and visceral fat using magnetic-activated cell sorting. Ovarian cancer cells were cultured in conditioned media (CM) obtained from ASCs to determine the cancer-promoting effects of ASCs. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, Boyden chamber assay, and western blotting were performed to determine the proliferative activity, migration ability, and activation of the JAK2/STAT3 pathway, respectively.
Results
CM from ASCs enhanced the migration of the ovarian cancer line, SKOV3, via activation of the JAK2/STAT3 signaling pathway. Interestingly, in response to ASC-CM, the ascites cells derived from an ovarian cancer patient showed an increase in growth and migration. The migration of ovarian cancer cells was suppressed by blocking the activation of JAK2 and STAT3 using a neutralizing antibody against interleukin 6, small molecular inhibitors (e.g., WP1066 and TG101348), and silencing of STAT3 using siRNA. Anatomical differences between S- and V-ASCs did not affect the growth and migration of the ovarian cancer cell line and ascites cells from the ovarian cancer patients.
Conclusion
ASCs may regulate the progression of ovarian cancer, and possibly provide a potential target for anticancer therapy.

Citations

Citations to this article as recorded by

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
Yanxin Chen, Yuxi Luo, Yunwei Liu, Daya Luo, Anwen Liu
Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef
The Role of Perirenal Adipose Tissue in Carcinogenesis—From Molecular Mechanism to Therapeutic Perspectives
Adriana Grigoraș, Cornelia Amalinei
Cancers.2025; 17(7): 1077. CrossRef
WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin
Jun Yang, Nanjing Li, Xinyu Zhao, Wenhao Guo, Yang Wu, Chunlai Nie, Zhu Yuan
Biochemical Pharmacology.2024; 221: 116040. CrossRef
Impact of Obesity and Lysosomal Dysfunction on Chemoresistance in Ovarian Cancer
Boyun Kim, Jewon Jung
Biomedicines.2024; 12(3): 604. CrossRef
SYT7 as a Potential Prognostic Marker Promotes the Metastasis of Epithelial Ovarian Cancer Cells by Activating the STAT3 Pathway
Yinguang Li, Fengping Shao, Ying Huang, Qian Yin, Jun Liu, Yunhe Zhao, Linjing Yuan
Molecular Carcinogenesis.2024; 63(12): 2441. CrossRef
Expression of LncRNAs in anterior capsule of lens in patients with pathologic myopia complicated with cataract
Yaru Hu, Yuchen Fan, Na Li, Che Xu, Jianfeng Wang
International Ophthalmology.2024;[Epub] CrossRef
Comparison of Interleukin-6 with Other Markers in Diagnosis of Ovarian Cancer
Magdalena Bizoń, Zofia Awiżeń-Panufnik, Włodzimierz Sawicki
Journal of Personalized Medicine.2023; 13(6): 980. CrossRef
The potential role of interleukins and interferons in ovarian cancer
Huldani Huldani, Sana Abdul-Jabbar Ali, F. Al-dolaimy, Ahmed Hjazi, Nikolenko Denis Andreevich, Khulood H. Oudaha, Abbas F. Almulla, Ali Alsaalamy, Shamam Kareem Oudah, Yasser Fakri Mustafa
Cytokine.2023; 171: 156379. CrossRef
ARF6 promotes hepatocellular carcinoma proliferation through activating STAT3 signaling
Yabing Hu, Yongchu Huang, Xiaohang Xie, Longshan Li, Yong Zhang, Xiaochao Zhang
Cancer Cell International.2023;[Epub] CrossRef
M1 Macrophages Enhance Survival and Invasion of Oral Squamous Cell Carcinoma by Inducing GDF15-Mediated ErbB2 Phosphorylation
Chunxu Lv, Shutong Li, Jingjing Zhao, Pishan Yang, Chengzhe Yang
ACS Omega.2022; 7(13): 11405. CrossRef
Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression
Hussein Chehade, Roslyn Tedja, Harry Ramos, Tejeshwar Singh Bawa, Nicholas Adzibolosu, Radhika Gogoi, Gil Mor, Ayesha B. Alvero
Cancers.2022; 14(9): 2267. CrossRef
The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer
Bruce A. Bunnell, Elizabeth C. Martin, Margarite D. Matossian, Courtney K. Brock, Khoa Nguyen, Bridgette Collins-Burow, Matthew E. Burow
Cancer and Metastasis Reviews.2022; 41(3): 549. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li
Frontiers in Oncology.2022;[Epub] CrossRef
Adaptation of metabolism to multicellular aggregation, hypoxia and obese stromal cell incorporation as potential measure of survival of ovarian metastases
Stephanie L.E. Compton, Emily S. Pyne, Lu Liu, Jack Guinan, Amanda A. Shea, Joseph P. Grieco, Madlyn I. Frisard, Eva M. Schmelz
Experimental Cell Research.2021; 399(1): 112397. CrossRef
Perirenal Adipose Tissue—Current Knowledge and Future Opportunities
Adriana Grigoraș, Raluca Anca Balan, Irina-Draga Căruntu, Simona Eliza Giușcă, Ludmila Lozneanu, Roxana Elena Avadanei, Andreea Rusu, Laura Adriana Riscanu, Cornelia Amalinei
Journal of Clinical Medicine.2021; 10(6): 1291. CrossRef
Mesenchymal Stem Cells in Adipose Tissue and Extracellular Vesicles in Ovarian Cancer Patients: A Bridge toward Metastatic Diffusion or a New Therapeutic Opportunity?
Gabriele Storti, Maria Giovanna Scioli, Bong-Sung Kim, Sonia Terriaca, Elena Fiorelli, Augusto Orlandi, Valerio Cervelli
Cells.2021; 10(8): 2117. CrossRef
Obesity Promotes Tumor Immune Evasion in Ovarian Cancer Through Increased Production of Myeloid-Derived Suppressor Cells via IL-6
Qiannan Yang, Bojun Yu, Jiuhong Kang, Ang Li, Jing Sun
Cancer Management and Research.2021; Volume 13: 7355. CrossRef
Impact of Computed Tomography-Based, Artificial Intelligence-Driven Volumetric Sarcopenia on Survival Outcomes in Early Cervical Cancer
Qingling Han, Se Ik Kim, Soon Ho Yoon, Taek Min Kim, Hyun-Cheol Kang, Hak Jae Kim, Jeong Yeon Cho, Jae-Weon Kim
Frontiers in Oncology.2021;[Epub] CrossRef
The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients
Izabela Szulc-Kielbik, Michal Kielbik, Marek Nowak, Magdalena Klink
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1876(2): 188639. CrossRef
A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine
Courtney K. Brock, Katherine L. Hebert, Maria Artiles, Maryl K. Wright, Thomas Cheng, Gabrielle O. Windsor, Khoa Nguyen, Madlin S. Alzoubi, Bridgette M. Collins-Burow, Elizabeth C. Martin, Frank H. Lau, Bruce A. Bunnell, Matthew E. Burow
Frontiers in Physiology.2021;[Epub] CrossRef
Dietary fats promote inflammation in Wistar rats as well as induce proliferation, invasion of SKOV3 ovarian cancer cells
Jafar Saeidi, Reza Motaghipur, Atefe Sepehrian, Mahnaz Mohtashami, Fatemeh Forooghi Nia, Ahmad Ghasemi
Journal of Food Biochemistry.2020;[Epub] CrossRef
Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma
Se Ik Kim, Taek Min Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jeong Yeon Cho, Yong Sang Song
Cancers.2020; 12(3): 559. CrossRef
Stomatin-like Protein 2 Promotes Tumor Cell Survival by Activating the JAK2-STAT3-PIM1 Pathway, Suggesting a Novel Therapy in CRC
Qiang Liu, Anqi Li, Lisha Wang, Wei He, Ling Zhao, Chao Wu, Shasha Lu, Xuanguang Ye, Huiyong Zhao, Xiaohan Shen, Xiuying Xiao, Zebing Liu
Molecular Therapy - Oncolytics.2020; 17: 169. CrossRef
Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics
Syeda Samira Afrose, Md. Junaid, Yeasmin Akter, Mousumi Tania, Meiling Zheng, Md. Asaduzzaman Khan
Drug Discovery Today.2020; 25(12): 2294. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management
Aeran Seol, Se Ik Kim, Yong Sang Song
Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth
Karen McLean, Lijun Tan, Danielle E. Bolland, Lan G. Coffman, Luke F. Peterson, Moshe Talpaz, Nouri Neamati, Ronald J. Buckanovich
Oncogene.2019; 38(9): 1576. CrossRef
Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer
Youngjin Han, HyunA Jo, Jae Hyun Cho, Danny N. Dhanasekaran, Yong Sang Song
International Journal of Molecular Sciences.2019; 20(4): 925. CrossRef
Adipose Stem Cells and Cancer: Concise Review
Rachel A. Sabol, Paulina Giacomelli, Adam Beighley, Bruce A. Bunnell
Stem Cells.2019; 37(10): 1261. CrossRef
Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells
Youngjin Han, Boyun Kim, Untack Cho, In Sil Park, Se Ik Kim, Danny N. Dhanasekaran, Benjamin K. Tsang, Yong Sang Song
Oncogene.2019; 38(45): 7089. CrossRef
Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity
Chin-Jui Wu, Vignesh Sundararajan, Bor-Ching Sheu, Ruby Yun-Ju Huang, Lin-Hung Wei
Cancers.2019; 12(1): 24. CrossRef
Pro‐inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF‐κB activation
Untack Cho, Boyun Kim, Soochi Kim, Youngjin Han, Yong Sang Song
Molecular Carcinogenesis.2018; 57(2): 235. CrossRef
Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway
Xue Hu, Jingjing Ma, Vikash Vikash, Jiao Li, Dandan Wu, Ya Liu, Jixiang Zhang, Weiguo Dong
Digestive Diseases and Sciences.2018; 63(1): 126. CrossRef
Perirenal Adiposity is Associated with Lower Progression-Free Survival from Ovarian Cancer
Yan Zhang, Adriana M. Coletta, Pamela K. Allen, Aaroh M. Parikh, Matthes Cox-Mattin, Larissa A. Meyer, Charlotte C. Sun, Karen M. Basen-Engquist, Karen H. Lu, Ann H. Klopp
International Journal of Gynecological Cancer.2018; 28(2): 285. CrossRef
Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer
Sanhong Li, Jilai Tian, Hongming Zhang, Shoubing Zhou, Xiyong Wang, Lei Zhang, Jiapeng Yang, Zhigang Zhang, Zhenling Ji
Apoptosis.2018; 23(5-6): 356. CrossRef
Role of the body mass index in the genesis of ascites in ovarian cancer: a forensic case and review of the literature
Isabella Aquila, Pietrantonio Ricci, Alessandra Oliverio, Santo Gratteri
BMJ Case Reports.2018; 11(1): e226491. CrossRef
The mechanism of alopolysaccharide protecting ulceralive colitis
Hu Lin, Li Honglang, Li Weifeng, Chen Junmin, Yang Jiantao, Gu Junjing
Biomedicine & Pharmacotherapy.2017; 88: 145. CrossRef
CO-releasing molecules CORM2 attenuates angiotensin II-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression
Ming-Horng Tsai, Chiang-Wen Lee, Lee-Fen Hsu, Shu-Yu Li, Yao-Chang Chiang, Ming-Hsueh Lee, Chun-Han Chen, Hwey-Fang Liang, Jia-Mei How, Pey-Jium Chang, Ching-Mei Wu, I-Ta Lee
Redox Biology.2017; 12: 377. CrossRef
Gene expression profiles of human subcutaneous and visceral adipose‐derived stem cells
Boyun Kim, Boram Lee, Mi‐Kyung Kim, Seung Pyo Gong, Noh Hyun Park, Hyun Hoon Chung, Hee Seung Kim, Jae Hong No, Woong Yang Park, Ae Kyung Park, Jeong Mook Lim, Yong Sang Song
Cell Biochemistry and Function.2016; 34(8): 563. CrossRef

14,698 View
387 Download
43 Web of Science
38 Crossref

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study: Hee Seung Kim, Hwa-Young Choi, Maria Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hyun Hoon Chung, Yong Beom Kim, Yong Sang Song; Cancer Res Treat. 2016;48(1):250-258. Published online March 6, 2015; DOI: https://doi.org/10.4143/crt.2014.324

Abstract PDF PubReader ePub

Purpose
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
Materials and Methods
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Results
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted noncomplete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
Conclusion
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.

Citations

Citations to this article as recorded by

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef
A clinicoradiological model based on clinical and CT features for preoperative prediction of histological classification in patients with epithelial ovarian cancers: a two-center study
Jiaojiao Li, Wenjiang Wang, Bin Zhang, Xiaolong Zhu, Di Liu, Chuangui Li, Fang Wang, Shujun Cui, Zhaoxiang Ye
Abdominal Radiology.2025;[Epub] CrossRef
Correlation between pre-operative platelets count and serum cancer antigen-125 level in epithelial ovarian carcer
Justina Omoikhefe Alegbeleye, Celestine Osita John
Indian Journal of Obstetrics and Gynecology Research.2024; 11(1): 17. CrossRef
Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015
Bing-Qian Tian, Shu-Wen Wang, Jing-Ying Xu, San-Gang Wu, Juan Zhou
Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line
Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar
Clinical and Translational Oncology.2024; 26(12): 3211. CrossRef
The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis
Zihan Zhang, Jinghe Lang
Journal of Medical Biochemistry.2024; 43(4): 323. CrossRef
Evaluation of inflammatory mediators as predictors ofprogression-free time (PFS) in patients with ovarian cancer(HGSOC) before and during treatment
Urszula Rychlik, Wiktor Szatkowski, Andrzej Kałamacki, Aneta Janicka, Karolina Górniak, Karolina Górniak, Paweł Blecharz
Diagnostyka Laboratoryjna.2024; 60(4): 231. CrossRef
Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors
Ke Huang, Shengjie Xu, Jiatong Wang, Lili Ge, Juan Xu, Xuemei Jia
Journal of Ovarian Research.2023;[Epub] CrossRef
Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR
Chuan-long Zhang, Xiao-chen Jiang, Yi Li, Xue Pan, Meng-qi Gao, Yan Chen, Bo Pang
Journal of Ovarian Research.2023;[Epub] CrossRef
Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer
Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kałamacki, Dorota Kiprian, Tomasz Banas
Cancers.2023; 15(14): 3607. CrossRef
Research Progress of the Relationship between Peripheral Blood Indexes and the Diagnosis, Treatment and Prognosis of Ovarian Cancer
洁严
Advances in Clinical Medicine.2023; 13(11): 17362. CrossRef
Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis
Fatemeh Tabatabaei, Hossein Tahernia, Arshin Ghaedi, Aida Bazrgar, Shokoufeh Khanzadeh
BMC Women's Health.2023;[Epub] CrossRef
Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia
Mega Sari Dewi, Roy Yustin Simanjuntak, Letta Sari Lintang, Muhammad Fahdhy, Deri Edianto, Makmur Sitepu
Majalah Obstetri & Ginekologi.2023; 31(3): 117. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li
Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of CA-125 Biomarker in Acute Appendicitis Patients: Correlation with Clinical Symptoms and Lab Results
Mojtaba Ahmadinejad, Seyed A. Hashemi, Alireza Shirzadi, Ali Soltanian, Jafar Ashrafi, Kourosh Kabir, Mahla Alizadeh
The Open Public Health Journal.2021; 14(1): 162. CrossRef
The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain
Na Wang, Cuiping Li, Yujie Yang, Yu Guan, Fengjiao Wang, Yan Wang, Wei Zhao
World Neurosurgery.2021; 149: 502. CrossRef
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art
Michal Mleko, Kazimierz Pitynski, Elzbieta Pluta, Aleksandra Czerw, Katarzyna Sygit, Beata Karakiewicz, Tomasz Banas
Cancer Management and Research.2021; Volume 13: 5491. CrossRef
The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis
Ting Chen, Jia‐Ling Wei, Ting Leng, Fei Gao, Shun‐yu Hou
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
International Journal of Molecular Sciences.2021; 22(24): 13650. CrossRef
Prognostic significance of preoperative circulating FAR and FCI scores in patients with ovarian cancer
Huige Wang, Yanjun Shen, Xiaoyan Ding, Yongfen Ding, Ling Cheng, Juan Lai
Clinica Chimica Acta.2020; 509: 252. CrossRef
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications
Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye
Journal of Ovarian Research.2020;[Epub] CrossRef
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer
Julie My Van Nguyen, Sarah Elizabeth Ferguson, Marcus Q Bernardini, Taymaa May, Stephane Laframboise, Liat Hogen, Geneviève Bouchard-Fortier
International Journal of Gynecological Cancer.2020; 30(9): 1378. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management
Aeran Seol, Se Ik Kim, Yong Sang Song
Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Associations between Blood Cell Profiles and Primary Open-Angle Glaucoma: A Retrospective Case-Control Study
Binghua Tang, Shengjie Li, Jianping Han, Wenjun Cao, Xinghuai Sun
Ophthalmic Research.2020; 63(4): 413. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma
Kosuke Yoshida, Nobuhisa Yoshikawa, Akira Shirakawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
Jie-Ping Chen, Qi-Dan Huang, Ting Wan, Hua Tu, Hai-Feng Gu, Jun-Ya Cao, Ji-Hong Liu
Journal of Ovarian Research.2019;[Epub] CrossRef
Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer
Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu
Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review
Naoko Komura, Seiji Mabuchi, Eriko Yokoi, Katsumi Kozasa, Hiromasa Kuroda, Tomoyuki Sasano, Yuri Matsumoto, Tadashi Kimura
International Journal of Clinical Oncology.2018; 23(1): 104. CrossRef
Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies
Zhe Zhao, Xinrui Zhao, Jingjing Lu, Jing Xue, Peishu Liu, Hongluan Mao
Archives of Gynecology and Obstetrics.2018; 297(4): 849. CrossRef
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis
Joanna L. Sylman, Annachiara Mitrugno, Michelle Atallah, Garth W. Tormoen, Joseph J. Shatzel, Samuel Tassi Yunga, Todd H. Wagner, John T. Leppert, Parag Mallick, Owen J. T. McCarty
Frontiers in Oncology.2018;[Epub] CrossRef
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer
Katarzyna Bednarska, Ewa Król, Ewa Głowacka, Hanna Romanowicz, Krzysztof Szyłło, Magdalena Klink, Zofia Sułowska, Marek Nowak
Medicine.2018; 97(12): e0180. CrossRef
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, Valentina Gallà, Filippo Greco, Claudia Casanova, Lucia Longo, Gennaro Cormio, Michele Orditura, Alessandra Bologna, Laura Zavallone, Jole Ventriglia, Elisena Franzese, Vera Loizzi, Donatella Giardina, Ev
Targeted Oncology.2018; 13(4): 469. CrossRef
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma
Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju
International Journal of Gynecological Cancer.2018; 28(6): 1108. CrossRef
Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis
Gaowen Chen, Lin Zhu, Yulu Yang, Yusheng Long, Xiangyuan Li, Yifeng Wang
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer
E Sun Paik, Minhee Shim, Hyun Jin Choi, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae
Cancer Biomarkers.2017; 17(4): 419. CrossRef
Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis
Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux
Gynecologic Oncology.2017; 145(3): 584. CrossRef
The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer
Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea, Vasilios Pergialiotis
Inflammation Research.2017; 66(6): 467. CrossRef
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma
Lihong Cong, Likuan Hu
International Immunopharmacology.2017; 46: 75. CrossRef
Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis
Yanlin Luo, Hee Seung Kim, Miseon Kim, Maria Lee, Yong Sang Song
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway
Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song
Cancer Research and Treatment.2017; 49(2): 338. CrossRef
Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma
Hongwei Zhang, Jiaqi Lu, Yingying Lu, Jiayi Zhou, Zehua Wang, Haiou Liu, Congjian Xu, Renato Franco
PLOS ONE.2017; 12(5): e0177520. CrossRef
Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis
Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao
BioMed Research International.2017; 2017: 1. CrossRef
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients
Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He
Oncotarget.2017; 8(40): 68938. CrossRef
Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer.
Urszula Rychlik, Ewa Wójcik, Jadwiga Tarapacz, Katarzyna Brandys, Zofia Stasik, Beata Kala, Jan K. Kulpa, Wiktor Szatkowski, Paweł Blecharz, Jerzy Jakubowicz
Diagnostyka Laboratoryjna.2017; 53(3): 139. CrossRef
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy
Yi Miao, Qin Yan, Shuangdi Li, Bilan Li, Youji Feng
Cancer Biomarkers.2016; 17(1): 33. CrossRef
Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma
Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu
Cancer Biomarkers.2016; 17(2): 205. CrossRef
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
Huimin Bai, Guisha Sha, Meizhu Xiao, Huiqiao Gao, Dongyan Cao, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen
Oncotarget.2016; 7(13): 15566. CrossRef
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer
Ghazala Khan, Suzanne E. Brooks, Ken I. Mills, Barbara-Ann Guinn
Biomarkers in Cancer.2015; 7: BIC.S28378. CrossRef

17,833 View
169 Download
52 Web of Science
48 Crossref

Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary: Jung-Yun Lee, Yu Ri Jo, Tae Hun Kim, Hee Seung Kim, Min A Kim, Jae Weon Kim, Noh Hyun Park, Yong-Sang Song; Cancer Res Treat. 2015;47(2):290-305. Published online August 29, 2014; DOI: https://doi.org/10.4143/crt.2014.004

Abstract PDF PubReader ePub

Purpose
The aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment for patients with primary mucinous epithelial ovarian cancer.
Materials and Methods
A retrospective study of patients with mucinous ovarian cancer between 1991 and 2010 was performed. The demographics and survival outcomes were compared between patients who underwent fertility-sparing surgery and those who underwent radical surgery.
Results
A total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan- Meier curve and the log rank test showed no difference in either recurrence-free survival (p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore, there was no significant difference in recurrence-free survival (p=0.126) or disease-specific survival (p=0.377) between the two groups, even when the analysis was limited to women below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).
Conclusion
Fertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be a safe option and one not associated with an increase in recurrence or mortality.

Citations

Citations to this article as recorded by

A Complex Case: Solid Unilateral Ovarian Mucinous Carcinoma Masquerading as Leiomyosarcoma in Postmenopausal Women
Naina Kumar, Immanuel Pradeep, Mishu Mangla, Annapurna Srirambhatla
Current Womens Health Reviews.2025;[Epub] CrossRef
Prognosis of stage-I ovarian mucinous tumors according to expansile and infiltrative types
Malek Bouhani, Stéphanie Schérier, Catherine Genestie, Mojgan Devouassoux-Shisheboran, Amandine Maulard, Francois Zaccarini, Alexandra Leary, Patricia Pautier, Philippe Morice, Sébastien Gouy
International Journal of Gynecological Cancer.2025; : 101641. CrossRef
Controversies in the management of mucinous ovarian tumors
Félix Blanc-Durand, Alexandra Leary
International Journal of Gynecological Cancer.2025; 35(3): 101679. CrossRef
Safety of fertility-sparing surgery in young women with stage I endometrioid epithelial and mucinous ovarian cancer: A population-based analysis
Jing Li, Huimin Qiao, Yunyun Liu, Chunxian Huang, Aoshuang Cheng, Zhongqiu Lin, Lijuan Wang, Huaiwu Lu
European Journal of Surgical Oncology.2024; 50(1): 107276. CrossRef
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand
Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, Yeh Chen Lee, Clare Scott, Pearly Khaw, Prue Allan, Claire Davies, John Andrews, Michelle Wilson, Janine M Lombard, Michelle Harrison, Heshani Nesfield, Anna DeFazio, Tarek Meniawy, Kylie L Gorringe
Australian and New Zealand Journal of Obstetrics and Gynaecology.2024; 64(4): 319. CrossRef
Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
Syed Abdul Mannan Hamdani, Musa Azhar, Abdul Wahab, Tahira Yasmeen, Neelam Siddiqui
South Asian Journal of Cancer.2023; 12(01): 081. CrossRef
Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer
Fulvio Borella, Marco Mitidieri, Stefano Cosma, Chiara Benedetto, Luca Bertero, Stefano Fucina, Isabelle Ray-Coquard, Annalisa Carapezzi, Domenico Ferraioli
Cancers.2023; 15(4): 1172. CrossRef
Safety of fertility sparing management in invasive mucinous ovarian carcinoma
Soyoun Rachel Kim, Ainhoa Madariaga, Liat Hogen, Danielle Vicus, Allan Covens, Carlos Parra-Herran, Stephanie Lheureux, Lilian T. Gien
Gynecologic Oncology.2023; 174: 129. CrossRef
Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas
Olivia Craig, Abhimanyu Nigam, Genevieve V. Dall, Kylie Gorringe
Cold Spring Harbor Perspectives in Medicine.2023; 13(9): a038190. CrossRef
Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma
Wei Lin, Dongyan Cao, Xiaohua Shi, Yan You, Jiaxin Yang, Keng Shen
Frontiers in Oncology.2022;[Epub] CrossRef
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?
Marc D. Algera, Willemien J. van Driel, Koen K. van de Vijver, Roy F.P.M. Kruitwagen, Christianne A.R. Lok
Current Opinion in Oncology.2022; 34(5): 497. CrossRef
Primary mucinous ovarian cancer: options for surgery and chemotherapy
Katherine C Kurnit, Michael Frumovitz
International Journal of Gynecological Cancer.2022; 32(11): 1455. CrossRef
Outcomes after Fertility-sparing Surgery for Women with Ovarian Cancer: A Systematic Review of the Literature
Alexandra Bercow, Roni Nitecki, Paula C. Brady, J.Alejandro Rauh-Hain
Journal of Minimally Invasive Gynecology.2021; 28(3): 527. CrossRef
Fertility preserving surgery in carcinoma ovary: a single institution experience
T. Subramanyeshwar Rao, KVVN Raju, Vikas Gupta, R. Rajagopalan Iyer
Indian Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review
Teska Schuurman, Sanne Zilver, Sanne Samuels, Winnie Schats, Frédéric Amant, Nienke van Trommel, Christianne Lok
Cancers.2021; 13(5): 1008. CrossRef
Fertility preservation in rare ovarian tumors
Anca Chelariu-Raicu, Lauren P Cobb, David M Gershenson
International Journal of Gynecological Cancer.2021; 31(3): 432. CrossRef
Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma
Dimitrios Nasioudis, Lakeisha Mulugeta-Gordon, Erin McMinn, Maureen Byrne, Emily M Ko, Lori Cory, Ashley F Haggerty, Nawar A Latif
International Journal of Gynecological Cancer.2021; 31(3): 480. CrossRef
Fertility-Sparing Surgery for Ovarian Cancer
Geoffroy Canlorbe, Nathalie Chabbert-Buffet, Catherine Uzan
Journal of Clinical Medicine.2021; 10(18): 4235. CrossRef
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata
Cancer Treatment Reviews.2021; 101: 102298. CrossRef
Options for the Treatment of Mucinous Ovarian Carcinoma
Olivia Craig, Carolina Salazar, Kylie L. Gorringe
Current Treatment Options in Oncology.2021;[Epub] CrossRef
Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival
Denghua Liu, Jing Cai, Aiwei Gao, Zehua Wang, Liqiong Cai
BMC Cancer.2020;[Epub] CrossRef
Fertility‐sparing treatment for early‐stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives
Rachel S. Mandelbaum, Maximilian Klar, Tsuyoshi Takiuchi, Liat Bainvoll, Shinya Matsuzaki, Richard J. Paulson, Koji Matsuo
Journal of Obstetrics and Gynaecology Research.2020; 46(8): 1263. CrossRef
Impact of uterus‐preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi‐institutional study with propensity score‐weighted analysis
Masato Yoshihara, Hiroaki Kajiyama, Satoshi Tamauchi, Shohei Iyoshi, Akira Yokoi, Shiro Suzuki, Michiyasu Kawai, Tetsuro Nagasaka, Kunihiko Takahashi, Shigeyuki Matsui, Fumitaka Kikkawa
International Journal of Gynecology & Obstetrics.2020; 150(2): 177. CrossRef
Tumeurs épithéliales de l’ovaire : préservation de la fertilité. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épi
C. Uzan, B. Courbiere, N. Chabbert-Buffet
Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 180. CrossRef
Mucinous Ovarian Carcinoma
Dan L. Longo, Philippe Morice, Sebastien Gouy, Alexandra Leary
New England Journal of Medicine.2019; 380(13): 1256. CrossRef
Early stage mucinous ovarian cancer: A review
Erin K. Crane, Jubilee Brown
Gynecologic Oncology.2018; 149(3): 598. CrossRef
Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers
Sebastien Gouy, Marine Saidani, Amandine Maulard, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice
The Oncologist.2018; 23(3): 324. CrossRef
Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers
Ignacio Zapardiel, Maria Cruz, Maria D. Diestro, Antonio Requena, Juan A. Garcia-Velasco
Human Reproduction Update.2016; 22(3): 281. CrossRef
Fertility-Sparing Surgery in Epithelial Ovarian Cancer
Enrica Bentivegna, Philippe Morice, Catherine Uzan, Sebastien Gouy
Future Oncology.2016; 12(3): 389. CrossRef
Mucinous ovarian cancer: A therapeutic review
Wen Xu, Jack Rush, Kirsty Rickett, Jermaine I.G. Coward
Critical Reviews in Oncology/Hematology.2016; 102: 26. CrossRef
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer
Robert Fruscio, Lorenzo Ceppi, Silvia Corso, Francesca Galli, Tiziana Dell'Anna, Federica Dell'Orto, Daniela Giuliani, Annalisa Garbi, Stefania Chiari, Costantino Mangioni, Rodolfo Milani, Irene Floriani, Nicoletta Colombo, Cristina Maria Bonazzi
British Journal of Cancer.2016; 115(6): 641. CrossRef
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna, S. Gouy, A. Maulard, P. Pautier, A. Leary, N. Colombo, P. Morice
Annals of Oncology.2016; 27(11): 1994. CrossRef

12,876 View
109 Download
36 Web of Science
32 Crossref

Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis: Hee Seung Kim, Taehun Kim, Eung Seok Lee, Hak Jae Kim, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Noh Hyun Park; Cancer Res Treat. 2013;45(3):193-201. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.193

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study was to determine whether chemoradiation (CCR) is efficient for improving prognosis, compared with systemic chemotherapy (SC), in patients with stage IVB cervical cancer who have distant lymphatic metastasis.
MATERIALS AND METHODS
Among 2,322 patients with cervical cancer between January 2000 and March 2010, 43 patients (1.9%) had stage IVB disease. After exclusion of 19 patients due to insufficient data and hematogenous metastasis, 24 patients (1%) who received CCR (n=10) or SC (n=14) were enrolled. We compared tumor response, progression-free survival (PFS) and overall survival (OS), and disease recurrence between CCR and SC.
RESULTS
Complete response rates were 60% and 0% after CCR and SC (p<0.01). Grade 3 or 4 leukopenia was more common in patients treated with CCR (24.4% vs. 9.1%, p=0.03), whereas grade 3 or 4 neuropenia was more frequent in those treated with SC (28.4% vs. 11.1%, p=0.03). Development of grade 3 proctitis occurred as a late radiotherapy (RT)-related toxicity in only one patient (10%) treated with CCR. In addition, squamous cell carcinoma and CCR were favorable prognostic factors for improvement of PFS (adjusted hazard ratios [HRs], 0.17 and 0.12; 95% confidence intervals [CIs], 0.04 to 0.80 and 0.03 to 0.61), and only CCR was significant for improvement of OS (adjusted HR, 0.15; 95% CI, 0.02 to 0.90). However, no differences in the rate and pattern of disease recurrence were observed between CCR and SC.
CONCLUSION
CCR may be more effective than SC for improving survival, and can be regarded as a feasible method with some caution regarding late RT-related toxicity for treatment of stage IVB cervical cancer with distant lymphatic metastasis.

Citations

Citations to this article as recorded by

Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review
Sea-Won Lee, Aeran Kim, Sung Jong Lee, Sung Hwan Kim, Jong Hoon Lee
Cancer Research and Treatment.2024; 56(1): 1. CrossRef
Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix
Shira Peleg Hasson, Shira Felder, Limor Helpman, Alexandra Taylor, Mihal Shalamov, Sireen Abuakar, Smadar Bauer, Ronnie Shapira-Frommer, Inbal Greenhouse, Jacob Korach, Tatiana Rabin, Jeffrey Goldstein, Akram Saad
International Journal of Gynecological Cancer.2023; 33(5): 683. CrossRef
Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review
David Viveros-Carreño, Santiago Vieira-Serna, Carlos Fernando Grillo - Ardila, Juliana Rodriguez, Nathalia Mora-Soto, Anuja Jhingran, Pedro T Ramirez, Rene Pareja
International Journal of Gynecological Cancer.2023; 33(7): 1057. CrossRef
Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab – An exploratory study
Rachel L. Wiley, Ioana L. Bondre, Randa Jalloul, Ann H. Klopp, Jolyn S. Taylor, Lois M. Ramondetta
Gynecologic Oncology Reports.2022; 40: 100963. CrossRef
Survival, treatment pattern, and treatment outcome in patients with cervical cancer metastatic to distant lymph nodes
Haoliang Lin, Dongyan Wang, Hui Li, Chuling Wu, Fengqian Zhang, Zhongqiu Lin, Tingting Yao
Frontiers in Oncology.2022;[Epub] CrossRef
Dynamic Nomogram Based on the Metastatic Number and Sites and Therapy Strategies Predicting the Prognosis of Patients with Metastatic Cervical Cancer
Yuan Ma, Jing Li, Xinyue Tan, Mengjiao Cai, Xiaozhi Zhang, Jinlu Ma
International Journal of Women's Health.2022; Volume 14: 1807. CrossRef
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
Satomi Hattori, Nobuhisa Yoshikawa, Kazumasa Mogi, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yoshiki Ikeda, Akira Yokoi, Kimihiro Nishino, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama
Current Oncology.2021; 28(3): 1663. CrossRef
A Nomogram-Based Risk Classification System Predicting the Overall Survival of Patients With Newly Diagnosed Stage IVB Cervix Uteri Carcinoma
Wenke Yu, Lu Huang, Zixing Zhong, Tao Song, Hong'en Xu, Yongshi Jia, Jinming Hu, Huafeng Shou
Frontiers in Medicine.2021;[Epub] CrossRef
Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer
Akshay Mangaj, Supriya Chopra, Remi A. Nout
Indian Journal of Medical Research.2021; 154(2): 303. CrossRef
Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study
Haoran Li, Yangyang Pang, Xi Cheng
Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy
Roberta Lazzari, Giulia Riva, Matteo Augugliaro, Andrea Vavassori, Samantha Dicuonzo, Federica Cattani, Stefania Comi, Nicoletta Colombo, Barbara Alicja Jereczek-Fossa
International Journal of Gynecological Cancer.2020; 30(5): 607. CrossRef
Sarcopenia as a Predictor of Survival Among Patients With Organ Metastatic Cervical Cancer
Nobuhisa Yoshikawa, Akira Shirakawa, Kosuke Yoshida, Satoshi Tamauchi, Shiro Suzuki, Fumitaka Kikkawa, Hiroaki Kajiyama
Nutrition in Clinical Practice.2020; 35(6): 1041. CrossRef
Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea
Sang Hee Youn, Yeon-Joo Kim, Sang-Soo Seo, Sokbom Kang, Myong Cheol Lim, Ha Kyun Chang, Sang-Yoon Park, Joo-Young Kim
International Journal of Gynecological Cancer.2020; 30(6): 764. CrossRef
Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma
Alexander Lin, Sirui Ma, Farrokh Dehdashti, Stephanie Markovina, Julie Schwarz, Barry Siegel, Matthew Powell, Perry Grigsby
International Journal of Gynecological Cancer.2019; 29(3): 487. CrossRef
Score for the Overall Survival Probability of Patients With First-Diagnosed Distantly Metastatic Cervical Cancer: A Novel Nomogram-Based Risk Assessment System
Shilong Zhang, Xin Wang, Zhanming Li, Wenrong Wang, Lishun Wang
Frontiers in Oncology.2019;[Epub] CrossRef
Special Focus on Stage IV Cervical Cancer Patients: A Decade Experience
Sophie Espenel, Max Adrien Garcia, Julien Langrand-Escure, Alexis Vallard, Jane Chloé Trone, Chloé Rancoule, Nicolas Vial, Pablo Moreno-Acosta, Céline Chauleur, Claire Boutet, Michel Peoc'h, Nathalie Prevot-Bitot, Jean Baptiste Guy, Nicolas Magné
Oncology.2019; 97(3): 125. CrossRef
Selection and identification of novel peptides specifically targeting human cervical cancer
Xiaomin Liu, Jingwen Peng, Jie He, Qiaoran Li, Jianbin Zhou, Xiaoqiu Liang, Shengsong Tang
Amino Acids.2018; 50(5): 577. CrossRef
Radiotherapy Improves the Survival of Patients With Metastatic Cervical Cancer: A Propensity-Matched Analysis of SEER Database
Kejie Huang, Mingfang Jia, Ping Li, Jianglong Han, Rui Zhang, Qin Li, Yunfeng Qiao, TangPeng Xu, Peng Ruan, Qibin Song, Yanbo Li, Zhenming Fu
International Journal of Gynecological Cancer.2018; 28(7): 1360. CrossRef
Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer
Shin Nishio, Koji Matsuo, Koji Yonemoto, Mototsugu Shimokawa, Masayuki Hosaka, Michiko Kodama, Takahito M. Miyake, Kimio Ushijima, Toshiharu Kamura, Shannon N. Westin, Pamela T. Soliman, Robert L. Coleman
Oncotarget.2018; 9(64): 32321. CrossRef
Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer
Tomoyuki Sasano, Seiji Mabuchi, Hiromasa Kuroda, Ryoko Takahashi, Katsumi Kozasa, Fumiaki Isohashi, Yasuo Yoshioka, M.D. Kazuhiko Ogawa, Tadashi Kimura
International Journal of Gynecological Cancer.2016; 26(3): 528. CrossRef
Advances in diagnosis and treatment of metastatic cervical cancer
Haoran Li, Xiaohua Wu, Xi Cheng
Journal of Gynecologic Oncology.2016;[Epub] CrossRef
Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients
Jung Ho Im, Hong In Yoon, Sunghoon Kim, Eun Ji Nam, Sang Wun Kim, Ga Won Yim, Ki Chang Keum, Young Tae Kim, Gwi Eon Kim, Yong Bae Kim
Radiation Oncology.2015;[Epub] CrossRef
Cancer of the cervix uteri
Adriana Bermudez, Neerja Bhatla, Eric Leung
International Journal of Gynecology & Obstetrics.2015;[Epub] CrossRef
HER2 as a novel therapeutic target for cervical cancer
Doo-Yi Oh, Seokhwi Kim, Yoon-La Choi, Young Jae Cho, Ensel Oh, Jung-Joo Choi, Kyungsoo Jung, Ji-Young Song, Suzie E. Ahn, Byoung-Gie Kim, Duk-Soo Bae, Woong-Yang Park, Jeong-Won Lee, Sangyong Song
Oncotarget.2015; 6(34): 36219. CrossRef
Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells
Peng Zhang, Hong Li, Bin Yang, Fan Yang, Lin-Lin Zhang, Qing-You Kong, Xiao-Yan Chen, Mo-Li Wu, Jia Liu
Genes & Cancer.2014; 5(5-6): 154. CrossRef

14,106 View
126 Download
25 Crossref

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer: Hee Jun Lee, Hee Seung Kim, Noh Hyun Park, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song; Cancer Res Treat. 2013;45(1):40-47. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.40

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study is to evaluate the efficacy and toxicity of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer (EOC).
MATERIALS AND METHODS
Clinical data were reviewed in 28 patients who received FOLFOX-4 as more than the second-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin as a 2-hour infusion, 200 mg/m2 of leucovorin as a 2-hour infusion, and bolus 400 mg/m2 on day 1, followed by a 22-hour infusion of 600 mg/m2 of 5-fluorouracil for two consecutive days every three weeks. In addition, its efficacy and toxicity were compared with those reported in in three previous relevant studies.
RESULTS
A total of 128 cycles of FOLFOX-4 were administered with the median number of five cycles (range, 1 to 10 cycles). In nine patients with measurable disease, complete response (CR) and partial response (PR) were observed in 0 (0%) and two (22.2%) patients, whereas in 19 patients with non-measurable disease, CR and PR were observed in 0 (0%) and five (26.3%) patients. Among all patients, grade 3 anemia, neutropenia, and thrombocytopenia were observed in two (7.1%), three (10.7%), and one (3.6%) patient, and grade 3 fatigue, nausea and vomiting, and peripheral neuropathy were observed in one (3.6%), two (7.1%), and three (10.7%) patients. In addition, median values of time to progressive disease and chemotherapy-specific survival were three months (range, 0 to 10 months) and nine months (range, 4 to 24 months).
CONCLUSION
FOLFOX-4 is feasible as salvage chemotherapy with acceptable toxicity for heavily pretreated patients with recurrent EOC.

Citations

Citations to this article as recorded by

Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells
Ashwaq A. Al-Mutairi, Mayson H. Alkhatib
Journal of Microencapsulation.2022; 39(5): 467. CrossRef
In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells
Alejandro Schcolnik-Cabrera, Mandy Juárez, Bernardo Oldak, Mayra Cruz-Rivera, Ana Flisser, Alfonso Dueñas-González, Vinnitsa Buzoianu-Anguiano, Sandra Orozco-Suarez, Fela Mendlovic
Archives of Medical Research.2020; 51(1): 65. CrossRef
Mucinous Cancer of the Ovary: Overview and Current Status
Abdulaziz Babaier, Prafull Ghatage
Diagnostics.2020; 10(1): 52. CrossRef
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
Vincenza Conteduca, Giorgia Gurioli, Lorena Rossi, Emanuela Scarpi, Cristian Lolli, Giuseppe Schepisi, Alberto Farolfi, Delia De Lisi, Valentina Gallà, Salvatore Luca Burgio, Cecilia Menna, Andrea Amadori, Lorena Losi, Dino Amadori, Maria Paola Costi, Ugo
BMC Cancer.2018;[Epub] CrossRef
Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study
An-Jen Chiang, Min-Yu Chen, Chia-Sui Weng, Hao Lin, Chien-Hsing Lu, Peng-Hui Wang, Yu-Fang Huang, Ying-Cheng Chiang, Mu-Hsien Yu, Chih-Long Chang
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Mucinous ovarian cancer: A therapeutic review
Wen Xu, Jack Rush, Kirsty Rickett, Jermaine I.G. Coward
Critical Reviews in Oncology/Hematology.2016; 102: 26. CrossRef
Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
Mohamed Elshebeiny, Walid Almorsy
Journal of the Egyptian National Cancer Institute.2016; 28(3): 183. CrossRef
The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score
Richard Sleightholm, Jason M. Foster, Lynette Smith, Wim Ceelen, Marcello Deraco, Yusuf Yildirim, Edward Levine, Cristobal Muñoz-Casares, Olivier Glehen, Asish Patel, Jesus Esquivel
Journal of Surgical Oncology.2016; 114(7): 779. CrossRef
Ginseng Purified Dry Extract, BST204, Improved Cancer Chemotherapy-Related Fatigue and Toxicity in Mice
Hyun-Jung Park, Hyun Soo Shim, Jeom Yong Kim, Joo Young Kim, Sun Kyu Park, Insop Shim
Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1. CrossRef
A Series of Malignant Ovarian Cancers Arising From Within a Mature Cystic Teratoma
Jonathan D. Black, Dana M. Roque, Monica C. Pasternak, Natalia Buza, Thomas J. Rutherford, Peter E. Schwartz, Shirley McCarthy, Elena Ratner
International Journal of Gynecological Cancer.2015; 25(5): 792. CrossRef
The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study
Fidia Mumtahana, Xinli Tiang, Teng Zhang, Baoxia Cui
International Journal of Cancer Therapy and Oncology.2014; 2(4): 020413. CrossRef
Gastrointestinal Adverse Effects in Advanced Colorectal Carcinoma Patients Treated with Different Schedules of FOLFOX
Nusrat Bano, Rahila Najam, Faaiza Qazi, Ahmed Mateen
Asian Pacific Journal of Cancer Prevention.2014; 15(19): 8089. CrossRef

11,859 View
97 Download
12 Crossref

Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer: Hee Seung Kim, Mi-Kyung Kim, Hak Jae Kim, Seung-Su Han, Jae Weon Kim; Cancer Res Treat. 2012;44(2):97-103. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.97

Abstract PDF PubReader ePub

PURPOSE
This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients.
MATERIALS AND METHODS
From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR.
RESULTS
The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings.
CONCLUSION
Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.

Citations

Citations to this article as recorded by

Radiomics feature is a risk factor for locally advanced cervical cancer treated using concurrent chemoradiotherapy based on magnetic resonance imaging: a retrospective study
Yuan Wang, Yanyan Yu, Lina Gu, Yunfeng Sun, Jiazhuo Yan, Hongxia Zhang, Yunyan Zhang
BMC Cancer.2025;[Epub] CrossRef
Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study
Jiaxin Wang, Huaijuan Guo, Jingjing Yang, Jingxian Mao, Ying Wang, Ruidong Gao, Xuebing Yan, Jie Wang
Frontiers in Oncology.2024;[Epub] CrossRef
The effectiveness of consolidation chemotherapy in high-risk early-stage cervical cancer patients following concurrent chemoradiation after radical surgery
Cong Wang, Chunli Fu, Changdong Ma, Qiuhong Qian, Fangfang He, Guangyu Zhang
Japanese Journal of Clinical Oncology.2023; 53(2): 122. CrossRef
Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis
Xiao Ma, Jin Fang, Lu Zhang, Yao Huang, Hui Shen, Xiaohua Ma, Shuixing Zhang, Bin Zhang
Critical Reviews in Oncology/Hematology.2023; 184: 103953. CrossRef
The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis
Lan Zhong, Kemin Li, Liang Song, Rutie Yin
Journal of Obstetrics and Gynaecology.2022; 42(5): 830. CrossRef
Role of Adjuvant Chemotherapy After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer
Lingna Kou, Tao Zhang, Xiling Yang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin Li
Future Oncology.2022; 18(16): 1917. CrossRef
Integration of Consolidation Chemotherapy After Concurrent Chemoradiation in the Treatment of Locally Advanced Uterine Cervical Cancer
V. S. Haritha, Laxmi Singotia, Rajesh Jain, A. K. Saxena, Shyamji Rawat, Lalit Patel
Indian Journal of Gynecologic Oncology.2022;[Epub] CrossRef
A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy
Ning Wu, Xing Su, Honglin Song, Ying Li, Fei Gu, Xiaoge Sun, Xiaofan Li, Guanghui Cheng
Cancer Control.2021;[Epub] CrossRef
Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
Nanda Horeweg, Prachi Mittal, Patrycja L. Gradowska, Ingrid Boere, Supriya Chopra, Remi A. Nout
Cancers.2021; 13(8): 1880. CrossRef
How should we stage and tailor treatment strategy in locally advanced cervical cancer? Imaging versus para-aortic surgical staging
Alejandra Martinez, Martina Aida Angeles, Denis Querleu, Gwenael Ferron, Christophe Pomel
International Journal of Gynecological Cancer.2020; 30(9): 1434. CrossRef
Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer
Jun Jiang, Wei Hong Wei, Tao Xu
Journal of Cancer Research Updates.2020; 9(1): 20. CrossRef
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
Seiji Mabuchi, Fumiaki Isohashi, Mika Okazawa, Fuminori Kitada, Shintaro Maruoka, Kazuhiko Ogawa, Tadashi Kimura
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer
Kyungmi Yang, Won Park, Seung Jae Huh, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee
Radiation Oncology Journal.2017; 35(1): 39. CrossRef
Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?
Simone Marnitz
Strahlentherapie und Onkologie.2017; 193(3): 236. CrossRef
CT-geplante HDR-Brachytherapie
Simone Marnitz-Schulze
InFo Onkologie.2017; 20(4): 10. CrossRef
Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
Jeanny Kwon, Keun-Yong Eom, In Ah Kim, Jae-Sung Kim, Young-Beom Kim, Jae Hong No, Kidong Kim
Cancer Research and Treatment.2016; 48(2): 632. CrossRef
A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes
Seiji Mabuchi, Fumiaki Isohashi, Takeshi Yokoi, Masahiko Takemura, Kiyoshi Yoshino, Yasuhiko Shiki, Kimihiko Ito, Takayuki Enomoto, Kazuhiko Ogawa, Tadashi Kimura
Gynecologic Oncology.2016; 141(2): 240. CrossRef
Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer
Yu Chang, Zhi-Yong Yang, Gui-Ling Li, Qin Li, Qin Yang, Ji-Quan Fan, Ying-Chao Zhao, Ying-Qiu Song, Gang Wu
International Journal of Gynecological Cancer.2016; 26(4): 770. CrossRef
Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy
Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen, Zi Liu
BMC Cancer.2015;[Epub] CrossRef
Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study
Ying Liu, Haoran Sun, Renju Bai, Zhaoxiang Ye
Radiation Oncology.2015;[Epub] CrossRef
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
Siriwan Tangjitgamol, Kanyarat Katanyoo, Malinee Laopaiboon, Pisake Lumbiganon, Sumonmal Manusirivithaya, Busaba Supawattanabodee
Cochrane Database of Systematic Reviews.2014;[Epub] CrossRef
Comparison of Clinical Efficacy of Three Different Neoadjuvant Approaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with Stage Ib2 and IIa2 Cervical Cancer
Jian-Hong Fu, Zhan Gao, Chen-Chen Ren, Yong-Gang Shi
Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2377. CrossRef
A Phase I Study of Concurrent Weekly Carboplatin and Paclitaxel Combined With Intensity-Modulated Pelvic Radiotherapy as an Adjuvant Treatment for Early-Stage Cervical Cancer Patients With Positive Pelvic Lymph Nodes
Seiji Mabuchi, Ryoko Takahashi, Fumiaki Isohashi, Takeshi Yokoi, Kimihiko Ito, Tateki Tsutui, Toshiyuki Ogata, Yasuo Yoshioka, Kazuhiko Ogawa, Tadashi Kimura
International Journal of Gynecological Cancer.2013; 23(7): 1279. CrossRef

11,028 View
97 Download
23 Crossref

First
Prev
Page of 1
Next
Last

Search